Patient Power: Does the Transplant Treatment Approach Still Have Value for Myeloma Patients?
Posted: Mar 28, 2018
Patient Power: Does the Transplant Treatment Approach Still Have Value for Myeloma Patients? image

Do myeloma patients still need transplants in the age  of so many newer treatment strategies? A panel of myeloma experts, including Carol Ann Huff MD, Suzanne Lentzsch, MD, PhD, and Sagar Lonial MD, FACP, addressed this topic during a recent interview.

Dr. Huff affirmed that for “the vast majority of people, the data supports that transplant is better than no transplant.”

There is still not enough information because long-term follow up isn’t yet available, but she suspects that with time there will be greater survival rates among those patients who have chosen the transplant treatment. The panel of myeloma experts agree that transplant is the best option for treatment care until further research and analyses say otherwise.

Does the Transplant Treatment Approach Still Have Value for Myeloma Patients? from Patient Power on Vimeo.

 

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811